Key Speakers
Labeeb Abboud, General Counsel, International AIDS Vaccine Initiative
Alice Albright, CFO, GAVI Alliance
Elizabeth Bailey, Principal, Commons Capital
Rashmi Barbhaiya, PhD, CEO and Managing Director, Advinus Therapeutics
Robert J. Beall, PhD, President and CEO, Cystic Fibrosis Foundation Therapeutics
Karen Bernstein, PhD, Co-Founder, Chairman, and Editor-in-Chief, BioCentury
Ted Bianco, PhD, FIBiol, Director of Technology Transfer, The Wellcome Trust
Joshua Boger, PhD, President and CEO, Vertex Pharmaceuticals
Hon. Sam Brownback, United States Senator; State of Kansas
Nancy L. Buc, Partner, Buc & Beardsley
Yves Champey, MD, Founding Chairman, Drugs for Neglected Diseases Initiative
Robert B. Chess, Chairman, Nektar Therapeutics
Gary M. Cohen, President, BD Medical, BD
Timothy R. Cote, MD, MPH; Director, Office of Orphan Product Development; US Food and Drug Administration
Jean-Francois de Lavison, Corporate VP, Global Health and International Affairs, Merieux Alliance
Thierry Darcis, MD, VP and General Manager, ViroPharma Europe
Nils Daulaire, MD, President and CEO; Global Health Council
R. Lee Douglas, Consultant and Visiting Scholar, UC Berkeley
Christopher D. Earl, PhD; President and CEO; BIO Ventures for Global Health
John W. Erickson, PhD, CSO, Sequoia Pharmaceuticals
Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), NIH
Mark B. Feinberg, MD, PhD, Vice President, Policy, Public Health and Medical Affairs, Merck Vaccines
Michael J. Free, PhD, Vice President and Senior Advisor for Technologies Program Leader, PATH
Sarah E. Frew, PhD, McLaughlin-Rotman Center for Public Health, University Health Network/University of Toronto
James A. Geraghty, Senior Vice President, Genzyme Corporation
Jan Gheuens, MD, PhD, Senior Program Officer, Infectious Diseases Development, Bill & Melinda Gates Foundation
Elizabeth McKee Gore, Executive Director, Partnership Alliances; United Nations Foundation
Henry G. Grabowski, PhD, Director, Program in Pharmaceuticals and Health Economics, Duke University Fuqua School of Business
William Greene, MD, General Partner, MPM Capital
Hon. James Greenwood, President and CEO; Biotechnology Industry Organization
Luca Guerzoni, CEO, Cambridge BioStability
Victoria Hale, PhD, Founder and Board Chair, Institute for OneWorld Health
Jeffrey Hackman, VP, Marketing, Emergent BioSolutions
Jenny Harry, PhD, BSc, CEO and Managing Director, Proteome Systems
Robert Hecht, PhD, Senior VP, Public Policy, International AIDS Vaccine Initiative
Karen Hedine, President and CEO, Micronics
Chris Hentschel, PhD, President and CEO, Medicines for Malaria Venture
Erik Iverson, Associate General Counsel, Bill & Melinda Gates Foundation
Andrew Jack, Pharmaceutical Correspondent, The Financial Times
Hannah E. Kettler, PhD, Program Officer, Global Health Initiatives, Bill & Melinda Gates Foundation
Rita Khanna, PhD, Legal Counsel, Aeras Global TB Vaccine Foundation
Fernando Kreutz, MD, PhD, Founder and CEO, FK Biotek
Jeffrey P. Kushan, Sidley Austin, Partner, LLP
Diana M. Lanchoney, MD, Executive Director, Developing World Strategic Integration, Merck Vaccines and Infectious Diseases
Ruth Levine, PhD, Senior Fellow and VP for Programs and Operations, Center for Global Development
Clement Lewin, PhD, VP, Marketing, Policy and Strategy, Acambis
Roger Longman, Managing Partner; Windhover Information Inc.
Christian Loucq, MD, Director, PATH's Malaria Vaccine Initiative
Thomas C. McConnell, Managing Director, Vanguard Ventures
Rajiv Malik, Senior Vice President, Advinus Therapeutics
John Maraganore, CEO, Alnylam Pharmaceuticals
Margaret G. McGlynn, President, Merck Vaccines and Infectious Diseases
Paolo Meoni, PhD, Drug Development Manager, CSIR Biosciences
Melinda Moree, PhD, former Director, PATH’s Malaria Vaccine Initiative
Solomon Nwaka, PhD, Manager, Genomic and Discovery Research, Special Program for Research and Training in Tropical Diseases, WHO
Jean-Pierre Paccaud, PhD, Director of Business Development, Drugs for Neglected Diseases Initiative
David P. Perry, CEO, Anacor Pharmaceuticals
Sergio Pimenta, Senior Manager, Global Manufacturing and Services, International Finance Corporation
J. Leighton Read, MD, General Partner, Alloy Ventures
Joerg Reinhardt, PhD, CEO, Vaccines and Diagnostics, Novartis Pharmaceuticals
James C. Robinson, PhD, MPH; Editor in Chief; Health Affairs
Giorgio Roscigno, MD, CEO, Foundation for Innovative New Diagnostics
Zeda Rosenberg, President and CEO, International Partnership for Microbicides
Una Ryan, PhD, OBE, CEO, AVANT Immunotherapeutics
James Sabry, MD, PhD, President and CEO, Cytokinetics
Professor Jeffrey D. Sachs, PhD; Director, the Earth Institute at Columbia University; Special Advisor to the United Nations Director-General Ban Ki-moon
Vijay B. Samant, President and CEO; Vical Inc.
Clifford M. Samuel, Senior Director, International Access Operations, Gilead Sciences
George A. Scangos, PhD, President and CEO, Exelixis, Inc.
Cheryl Scott, Chief Operating Officer, Bill & Melinda Gates Foundation
Alan Shaw, PhD, President and CEO, VaxInnate, Inc.
Lawrence A. Siebert, President and CEO, Chembio Diagnostics, Inc.
Peter Singer, MD, MPH, FRCPC, FRSC, Senior Scientist and Professor of Medicine, McLaughlin-Rotman Center for Public Health, University Health Network/University of Toronto
Mel Spigelman, MD, Director, Research and Development, Global Alliance for TB Durg Development
Alan Taggart, Vice President, Government Project Management, MedImmune, Inc.
Kate Taylor, MBBS, MPH, Vice President, Market Access, GlaxoSmithKline Biologicals
Wendy Taylor, Founder and VP, Strategy and Operations, BIO Ventures for Global Health
Henri A. Termeer, President and CEO, Genzyme Corporation
Michael C. Venuti, CEO, BioSeek, Inc.
Saul Walker, Senior Access to Medicines Policy Advisor, Health Services Team, UK Department for International Development
Gregory M. Weinhoff, MD, Partner, CHL Medical Partners
Rear Admiral R. Timothy Ziemer, Coordinator, President's Malaria Initiative, USAID